Phase 2 Chronic Kidney Disease Trial, Recruiting NCT06843902 Sponsor: Massachusetts General Hospital Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 2 Chronic Kidney Disease Trial, Recruiting

NCT06843902
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You were born female
  • You are living with HIV and have been on a stable HIV treatment regimen for at least 180 days (about 6 months)
  • You are between 45 and 75 years old
  • You have at least one of the following: type 2 diabetes, reduced kidney filtering function (confirm with trial site), or a certain level of protein detected in your urine (confirm with trial site)
  • A special heart imaging scan done during screening shows that blood flow to your heart is reduced below a certain level (confirm with trial site)

Who may not be able to join:

  • You are currently taking a type of diabetes medication called an SGLT2 inhibitor (such as empagliflozin or dapagliflozin)
  • You have a known allergy to SGLT2 inhibitor medications
  • You have type 1 diabetes, or a form of diabetes that has caused a dangerous condition called ketoacidosis
  • You have a history of a kidney condition called polycystic kidney disease
  • You have a history of a heart attack, stroke, or a procedure to open blocked heart arteries
  • You have chest pain related to your heart (either stable or unstable)
  • You have a history of heart failure
  • Your blood sugar control (measured by a test called HbA1c) is too high at the time of screening
  • Your blood pressure is very high at the time of screening (confirm with trial site)
  • Your kidney filtering function is below a certain level (confirm with trial site)
  • You are currently on dialysis (hemodialysis or peritoneal dialysis)
  • Your immune cell count (CD4) is below 400 (confirm with trial site)
  • You are currently taking steroid tablets, injections, or infusions, or immune-suppressing medications (not including creams, certain anti-inflammatory tablets, or UV therapy)
  • You are pregnant or breastfeeding
  • You have a known allergy to the substances used in the heart imaging scan (confirm with trial site)
  • You are already taking part in another research study that would conflict with this one
  • You have had frequent urinary tract infections (2 or more in 6 months, or 3 or more in a year) or frequent vaginal yeast infections (2 or more in 6 months, or 3 or more in a year)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Markella V Zanni, MD, MGH/HMS

Phone: 617-724-6091

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
17 April 2025
Est. completion
1 March 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Coronary Flow Reserve; Ectopic Adipose Tissue

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov